ibd

Ferric maltol (Iron(III) 2-methyl-4-oxo-4H-pyran-3-olate) is a ferric, non-salt-based oral iron formulation demonstrating improved tolerance in patients with previous intolerance to other iron formulations.

1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palmatine has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases.

Sibofimloc (Antibiotic-202), an antibiotic compound, is used in treating bacterial infections.

NS6180 is a potent and selective KCa3.1 channel inhibitor(IC50= 9 nM). It prevents T-cell activation and inflammation.

Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

Palmatine chloride an isoquinoline alkaloid, is an important medicinal herbal extract with diverse pharmacological and biological properties.

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity, physicochemical properties and pharmacokinetic profile.

Indole-3-pyruvic acid (3-(3-Indolyl)-2-oxopropanoic acid) is a compound involved in the biosynthesis of Indole-3-acetic acid, a plant hormone which plays important roles in regulating growth and responses to environmental changes.

Tiomolibdate diammonium (NSC-286644) is an inhibitor of superoxide dismutase 1 (SOD1) exerting antiangiogenic and antitumor activities. Tiomolibdate diammonium inhibits the activities of cuproenzymes, including SOD1 and COX.

ATN-224 is a second-generation analogue of ammonium tetrathiomolybdate, acting as a novel copper chelator. It demonstrates anti-angiogenic and anti-tumor properties by inhibiting CuZn superoxide dismutase 1 (SOD1).

Kibdelone C is a member of a family of natural heterocyclic polyketides first isolated from a soil actinomycete, Kibdelosporangium. Kibdelones have been described as having potent and selective cytotoxicity against a panel of human tumor cell lines, and kibdelone C has low nanomolar effectiveness in these assays. Kibdelone C disrupts the actin cytoskeleton without directly binding actin or affecting its polymerization in vitro.

BIBD-124, with an IC50 value of 9.51 nM, effectively binds to amyloid beta (Aβ) plaques. The fluorinated variant, [18F]BIBD-124, serves as a radiotracer for imaging Aβ plaques [1].

Kibdelin D exhibits resistance against Gram-positive bacteria, showing effectiveness comparable to Vancomycin against Staphylococcus aureus (including methicillin-resistant strains).

Kibdelin A is effective against Gram-positive bacteria and exhibits effects similar to Vancomycin against Staphylococcus aureus (including methicillin-resistant strains).

Kibdelin C1 exhibits resistance against Gram-positive bacteria and demonstrates similar effectiveness to Vancomycin in combatting Staphylococcus aureus, including methicillin-resistant strains (MRSA).

Kibdelin B exhibits resistance against Gram-positive bacteria and demonstrates effects similar to Vancomycin, particularly against Staphylococcus aureus, including methicillin-resistant strains.

Kibdelone A, a natural heterocyclic polyketide, was first isolated from the soil actinomycete Kibdelosporangium. It exhibits potent and selective cytotoxicity against various human tumor cell lines, in addition to showing significant antibacterial and nematocidal activity.

Kibdelin C2 exhibits resistance against Gram-positive bacteria and demonstrates efficacy against Staphylococcus aureus (including methicillin-resistant strains) comparable to that of Vancomycin.

Plogosertib (CYC140) is an orally active, selective, potent, and ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.Plogosertib exhibits antiproliferative and anticancer activity and can be used for the study of solid and hematologic tumors. and hematologic tumors.

Pyrotinib dimaleate is a selective EGFR/HER2 dual inhibitor with IC50 values ​​of 13 and 38 nM, respectively, for the treatment of HER2-positive breast cancer.

Lapatinib ditosylate (Lapatinib tosilate) monohydrate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib ditosylate monohydrate therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury.

Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.

Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is a highly potent and selective MEK inhibitor that specifically inhibits MEK1/2 (IC50: 2 nM).

Lapatinib Ditosylate (Tykerb ditosylate) is an effective EGFR and ErbB2 inhibitor (IC50: 10.8/9.2 nM for EGFR/ErbB2).